Status:

COMPLETED

Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects

Lead Sponsor:

GlaxoSmithKline

Conditions:

Infections, Papillomavirus

Eligibility:

FEMALE

20-60 years

Phase:

PHASE3

Brief Summary

Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity and safety of the GSK ...

Detailed Description

Subjects were aged 15-55 years at the time of entry into the primary study (NCT00196937). No vaccine was administered in this extension study. Results on outcome measures describing analyses on other...

Eligibility Criteria

Inclusion

  • Subjects who the investigator believed that they could and would comply with the requirements of the protocol.
  • A female who had been enrolled in NCT00196937 study and received three doses of HPV-16/18 vaccine.
  • Written informed consent obtained from the subject.

Exclusion

  • Use of any investigational or non-registered product (drug or vaccine) or planned use during the study period.
  • Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs occurring less than three months prior to blood sampling.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
  • Administration of immunoglobulins and/or any blood products within the three months preceding blood sampling.
  • Administration or planned administration of any HPV vaccine, other than the three doses of HPV-16/18 vaccine administered in NCT00196937 study.

Key Trial Info

Start Date :

September 22 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 3 2015

Estimated Enrollment :

525 Patients enrolled

Trial Details

Trial ID

NCT00947115

Start Date

September 22 2009

End Date

February 3 2015

Last Update

October 30 2020

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

GSK Investigational Site

Munich, Bavaria, Germany, 80637

2

GSK Investigational Site

Würzburg, Bavaria, Germany, 97070

3

GSK Investigational Site

Berlin, Germany, 12200

4

GSK Investigational Site

Bydgoszcz, Poland, 85-079